Literature DB >> 17015625

Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones.

Stéphanie Matrat1, Nicolas Veziris, Claudine Mayer, Vincent Jarlier, Chantal Truffot-Pernot, Juliette Camuset, Elisabeth Bouvet, Emmanuelle Cambau, Alexandra Aubry.   

Abstract

We investigated the enzymatic efficiency and inhibition by quinolones of Mycobacterium tuberculosis DNA gyrases carrying the previously described GyrA G88C mutation and the novel GyrA G88A mutation harbored by two multidrug-resistant clinical strains and reproduced by site-directed mutagenesis. Fluoroquinolone MICs and 50% inhibitory concentrations for both mutants were 2- to 43-fold higher than for the wild type, demonstrating that these mutations confer fluoroquinolone resistance in M. tuberculosis.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17015625      PMCID： PMC1694005          DOI： 10.1128/AAC.00944-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

Authors:  Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon
Journal:  Am J Respir Crit Care Med       Date:  2003-02-15       Impact factor: 21.405

Review 2.  Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases.

Authors:  Kevin D Corbett; James M Berger
Journal:  Annu Rev Biophys Biomol Struct       Date:  2004

3.  Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand.

Authors:  Pannamthip Pitaksajjakul; Waranya Wongwit; Wantanee Punprasit; Boonchuy Eampokalap; Sharon Peacock; Pongrama Ramasoota
Journal:  Southeast Asian J Trop Med Public Health       Date:  2005       Impact factor: 0.267

4.  Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria.

Authors:  G Sindelar; X Zhao; A Liew; Y Dong; T Lu; J Zhou; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

5.  Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid.

Authors:  E Cambau; F Bordon; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

Review 6.  Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection.

Authors:  Joaquim Ruiz
Journal:  J Antimicrob Chemother       Date:  2003-04-14       Impact factor: 5.790

7.  Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  Augustine F B Cheng; Wing W Yew; Edward W C Chan; Miu L Chin; Mamie M M Hui; Raphael C Y Chan
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

8.  Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis.

Authors:  Edward D Chan; Valerie Laurel; Matthew J Strand; Julanie F Chan; Mai-Lan N Huynh; Marian Goble; Michael D Iseman
Journal:  Am J Respir Crit Care Med       Date:  2004-01-23       Impact factor: 21.405

9.  Geographically dependent distribution of gyrA gene mutations at codons 83 and 87 in Salmonella Hadar, and a novel codon 81 Gly to His mutation in Salmonella Enteritidis.

Authors:  B A Lindstedt; L Aas; G Kapperud
Journal:  APMIS       Date:  2004-03       Impact factor: 3.205

10.  Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.

Authors:  Alexandra Aubry; Xiao-Su Pan; L Mark Fisher; Vincent Jarlier; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191
View more
  24 in total

1.  GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples.

Authors:  A Lacoma; N García-Sierra; C Prat; J Maldonado; J Ruiz-Manzano; L Haba; P Gavin; S Samper; V Ausina; J Domínguez
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

Review 2.  A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system.

Authors:  Fernanda Maruri; Timothy R Sterling; Anne W Kaiga; Amondrea Blackman; Yuri F van der Heijden; Claudine Mayer; Emmanuelle Cambau; Alexandra Aubry
Journal:  J Antimicrob Chemother       Date:  2012-01-25       Impact factor: 5.790

3.  Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates.

Authors:  Florence Brossier; Nicolas Veziris; Alexandra Aubry; Vincent Jarlier; Wladimir Sougakoff
Journal:  J Clin Microbiol       Date:  2010-03-24       Impact factor: 5.948

Review 4.  Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis.

Authors:  Hanna Nebenzahl-Guimaraes; Karen R Jacobson; Maha R Farhat; Megan B Murray
Journal:  J Antimicrob Chemother       Date:  2013-09-20       Impact factor: 5.790

5.  DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis.

Authors:  Alix Pantel; Stéphanie Petrella; Stéphanie Matrat; Florence Brossier; Sylvaine Bastian; Delphine Reitter; Vincent Jarlier; Claudine Mayer; Alexandra Aubry
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

6.  Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis.

Authors:  Alix Pantel; Stéphanie Petrella; Nicolas Veziris; Florence Brossier; Sylvaine Bastian; Vincent Jarlier; Claudine Mayer; Alexandra Aubry
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

7.  Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?

Authors:  Stéphanie Matrat; Emmanuelle Cambau; Vincent Jarlier; Alexandra Aubry
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

8.  Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.

Authors:  Pooja Singh; Amita Jain; Pratima Dixit; Shantanu Prakash; Indu Jaiswal; Vimala Venkatesh; Mastan Singh
Journal:  J Antibiot (Tokyo)       Date:  2014-07-23       Impact factor: 2.649

9.  Comprehensive treatment of extensively drug-resistant tuberculosis.

Authors:  Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

10.  Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.

Authors:  Stéphanie Matrat; Alexandra Aubry; Claudine Mayer; Vincent Jarlier; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.